Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Depression in Patients Being Treated for Head and Neck Cancer.

X
Trial Profile

Prevention of Depression in Patients Being Treated for Head and Neck Cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depressive disorders
  • Focus Therapeutic Use
  • Acronyms PROTECT
  • Most Recent Events

    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 22 Mar 2013 Primary endpoint 'Quick-Inventory-of-Depressive-Symptomology-Self-Report' has been met according to results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top